Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study

BACKGROUND/AIMS: Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively control nocturnal acid breakthrough. To evaluate the pharmacodynamics of tegoprazan versus dexlansoprazole regarding nocturnal acid breakthrough...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Sungpil, Choi, Hee Youn, Kim, Yo Han, Choi, SeungChan, Kim, Seokuee, Nam, Ji Yeon, Kim, Bongtae, Song, Geun Seog, Lim, Hyeong-Seok, Bae, Kyun-Seop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840922/
https://www.ncbi.nlm.nih.gov/pubmed/36317518
http://dx.doi.org/10.5009/gnl220050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840922/
https://www.ncbi.nlm.nih.gov/pubmed/36317518
http://dx.doi.org/10.5009/gnl220050

Ejemplares similares